Radioactive 'Bullets' aim to stop ovarian cancer spread in new trial

NCT ID NCT06504147

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a single injection of Radspherin®, a radioactive treatment given directly into the abdomen, for people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has spread to the lining of the belly. About 114 participants will receive either standard care plus Radspherin® or standard care alone. The goal is to see if Radspherin® delays cancer growth after chemotherapy and surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH GRADE ENDOMETRIOID FALLOPIAN TUBE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Clinica Universidad de Navarra

    RECRUITING

    Madrid, Spain

  • Clinica Universidad de Navarra

    RECRUITING

    Pamplona, Spain

  • Fondazione Policlinico Universitario A. Gemelli IRCCS

    RECRUITING

    Roma, Italy

  • Hospital Universitari de Bellvitge

    RECRUITING

    Barcelona, Spain

  • Hospital Universitari i Politècnic La Fe

    RECRUITING

    Valencia, Spain

  • Imperial College Healthcare NHS Trust

    RECRUITING

    London, United Kingdom

  • Moffitt Cancer Center

    RECRUITING

    Tampa, Florida, 33612, United States

  • The Norwegian Radiumhospital

    RECRUITING

    Oslo, Norway

  • UZ Leuven

    RECRUITING

    Leuven, Belgium

  • University Hospital Southampton NHS Foundation Trust

    RECRUITING

    Southampton, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.